AAA	Amlodipine vs. ARB in Atherosclerosis
ADEPT	Addition of the AT1 Receptor Antagonist Eprosartan to ACE Inhibitor Therapy in Chronic Heart Failure
AMADEO	Telmisartan vs. Losartan in Hypertensive Type 2 Diabetic Patients with Overt Nephropathy
CAPRAF	Candesartan in the Prevention of Relapsing Atrial Fibrillation
CASE-J	Candesartan Antihypertensive Survival Evaluation in Japan
CATCH	Italian Candesartan Assessment in the Treatment of Cardiac Hypertrophy
CENTRO	Candesartan on Atherosclerotic Risk Factors
CHARM	Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity
CVIP	Cardiovascular Irbesartan Project
DETAIL	Diabetics Exposed to Telmisartan and Enalapril
DIRECT	Diabetic Retinopathy Candesartan Trials
E-COST	Efficacy of Candesartan on Outcome in Saitama Trial
ELITE	Evaluation of Losartan in the Elderly
EPAS	Endothelial Protection, AT1 Blockade and Cholesterol-Dependent Oxidative Stress
EUTOPIA	European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis
GISSI-AF	Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardio-Atrial Fibrillation
HEAAL	Heart Failure Endpoint Evaluation of Angiotensin II Antagonist Losartan
HKVIN	Hong Kong Study Using Valsartan in IgA Nephropathy
IDNT	Irbesartan Diabetic Nephropathy Trial
IMPROVE	Irbesartan in the Management of Proteinuric Patients at High Risk of Vascular Events
INNOVATION	Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy
I-PRESERVE	Irbesartan in Heart Failure with Preserved Ejection Fraction
IRMA-	Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria
ISLAND	Irbesartan and Lipoic Acid in Endothelial Dysfunction
JLIGHT	Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients
LIFE	Losartan Intervention for Endpoint Reduction
MARVAL	Microalbuminuria Reduction with Valsartan
MITEC	Media Intima Thickness Evaluation with Candesartan Cilexetil
MOSES	Morbidity and Mortality after Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention
NAVIGATOR	Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research
ONTARGET	Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial
OPTIMAAL	Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan
PRoFESS	Prevention Regimen for Effectively Avoiding Second Strokes
RENAAL	Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan
REPLACE	Replacement of Angiotensin-Converting Enzyme Inhibition
RESOLVD	Randomized Evaluation of Strategies for Left Ventricular Dysfunction
ROAD	Renoprotection of Optimal Antiproteinuric Doses
SCOPE	Study on Cognition and Prognosis in the Elderly
SILVHIA	Swedish Irbesartan Left Ventricular Hypertrophy Versus Atenolol
SMART	Shiga Microalbuminuria Reduction Trial
TRANSCEND	Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease
T-VENTURE	Inhibitory Effect of Valsartan against Progression of Left Ventricular Dysfunction after Myocardial Infarction
VALERIA	Valsartan in Combination with Lisinopril in Hypertensive Patients with Microalbuminuria
Val-HeFT	Valsartan Heart Failure Trial
VALIANT	Valsartan in Acute Myocardial Infarction
VIP	Valsartan Inhibits Platelets
VIVALDI	Investigate the Efficacy of Telmisartan versus Valsartan in Hypertensive Type 2 Diabetic Patients with Overt Nephropathy